Salipro® Enables Discovery and Cryo‑EM Epitope Mapping of CXCR4 Antibodies

We’re excited to share a recent update from our collaboration with Bio‑Rad and ATEM, advancing antibody discovery for the challenging GPCR target CXCR4.

Using Salipro®‑CXCR4 (wildtype) to stabilize the receptor in a native‑like lipid environment, Bio‑Rad’s Pioneer™ Antibody Discovery Platform generated a diverse panel of high‑affinity CXCR4 antibodies. Several outperformed the benchmark antibody ulocuplumab (BMS) in affinity, functionality, and developability.

Together with ATEM, we advanced this work to cryo‑EM epitope mapping, revealing distinct antibody epitopes on CXCR4. This structural insight is key for understanding mechanism of action, differentiating candidates, and enabling clearly defined, defensible IP through novel epitope claims.

Salipro® enables a seamless, end‑to‑end workflow for antibody discovery against difficult membrane protein targets, from native-state stabilization, to antibody discovery, to high‑resolution structural insight.

We thank the teams at Bio‑Rad and ATEM for our excellent collaboration.